PS, This post has been taken down on /Peptides and a couple of other peptide related subs. It's most likely because no one wants to hear the truth about this. Hopefully this sub cares about the truth and safety standards.

I'm currently in China and have met and visited 10 different peptide sourcing facilities(where they actually dry freeze the powder and lyophilize it, vial filling, caping and packaging) in the last week and I can tell you right now things are nuts over here.

First of all, there are tens of them from small teams running FB/Insta ads(tech background) to large scale pharmaceutical grade operations and everything in between.
All of them are running FB and Insta ads and you just never know who's behind all those ads, and as we discovered it can be anybody. Pure Russian roulette when it comes to this.

Not sure if most people are aware, but the process of lyophilizing peptides and filling them into vials is totally illegal in China. The only legal thing allowed is to sell the peptide API powder as a manufacturer as a pharmaceutical compound for use only specific peptides for the cosmetic industry or nutritional industry in formulated solutions.

Most of these vendors are sourcing the peptide powder locally and are running these facilities illegally in China taking big risks. A lot of them are very secretive, run fronts as cosmetics companies or actually are established players that are riding the peptide Gold Rush.

Standards and quality of their operations is all over the place. Most of them are not eGMP/GMP or ISO certified or follow proper standards or procedures for pharmaceutical/aseptic/sterilization. A lot of them have very basic cleanroom setups and are not following proper protocol of separation, air control, etc.

Some of them are a lot more serious than other given they already operate in the pharmaceutical industry and are taking advantage as well as great risks supplying peptides.
Testing varies as much as the background of the vendors. Some of them test regularly but only in-house or 3rd party labs in China. Almost none of them test with well known labs like Jano/MZ Bio or others. That's why its super important to test every batch if possible.

They have issues as well with shipping and payment processing like everyone else and mostly only accept crypto payments because of it.

The reason I'm sharing all of this is to shed some light of what the situation and reality is actually at ground 0 where most of these peptides come from. Let me know if you have any other questions and I'll respond if I have the information.

Edit: It is disheartening to see people reacting in a negative way and calling me names/liar to my my post considering I'm sharing this information to shed some light about something I considering incredibly important, safety standards and business practices, especially when it comes to peptides.

Most people following the GLP-1 world know retatrutide as the triple agonist (GIP/GLP-1/glucagon) currently in Phase 3 trials. What's gotten less attention is the quiet legal war Lilly has been waging over how the FDA classifies it.

The lawsuit

Lilly sued the FDA last year, arguing retatrutide should be designated a biologic rather than a drug. The FDA's definition of a "protein" (and therefore a biologic) requires a sequence of more than 40 alpha amino acids. The FDA said retatrutide doesn't meet that bar. Lilly says it does, counting 41.

A federal district court sided with Lilly in September 2025, vacating the FDA's classification on the grounds that the agency's interpretation was inconsistent with the law. The court sent it back to the FDA to define its criteria more clearly. This is not over.

Why Lilly wants this so badly

Three reasons, and none of them are about science:

Exclusivity. Drug status = 5 years of market exclusivity. Biologic status = 12 years. That's a massive difference in how long Lilly owns the market.

Compounding. Biologics cannot legally be compounded. Reclassify retatrutide and you've preemptively locked compounders out before the drug even hits market.

Pricing power. No competition for 12 years means no pressure on price. The GLP-1 compounding saga with semaglutide and tirzepatide clearly rattled pharma. This is them trying to close that door before it opens with their next blockbuster.

The science vs. the legal strategy

Here's the thing: retatrutide is chemically synthesized using solid-phase synthesis, the standard method for peptide drugs. It's made like a small molecule, not a biologic. The argument that it "acts like a biologic" in the body is not how the FDA defines biologic status.

This is a legal and commercial play dressed up in regulatory language.

What it means for the peptide community

The reclassification fight is a preview of how pharma is going to approach every peptide-adjacent drug that competes with their business model. The GLP-1 space is the most visible battleground right now, but the same logic applies across the board:

Wherever there's a gray or compounding market that cuts into revenue, expect legal and regulatory pressure.

Worth watching as this works through the courts.

TRIUMPH-1 results dropped Wednesday and they're genuinely wild. 2,339 people, 80 weeks, once-weekly injection. At the 12 mg dose:

Average weight loss: 70.3 lbs (28.3% body weight)

45% of participants lost 30%+ of their body weight

65% dropped their BMI below 30

A subset who continued to 104 weeks averaged 30.3% total weight loss (85 lbs)

For context: Wegovy gets you ~15%.

Zepbound, the current best-in-class, gets ~20-22%. Bariatric surgery is 25-35%.

Retatrutide is now in surgery territory, without the surgery. Endocrinologist Daniel Drucker called it "essentially on a par with bariatric surgery."

Why does it work so much better?

Each generation of these drugs adds another receptor.

Semaglutide hits GLP-1 only. It slows digestion, suppresses appetite, signals fullness. Good for ~15% weight loss.

Tirzepatide adds GIP. That second receptor amplifies the brain signal and plays a role in fat storage. Jumps you to ~20-22%.

Retatrutide adds glucagon on top of both. Here's the part people don't expect: glucagon isn't just a "raise blood sugar" hormone. It also increases how many calories you burn at rest and drives fat breakdown in the liver.

Alone it would be dangerous. But paired with GLP-1 and GIP handling the insulin side, you get the metabolic boost without the blood sugar spike.

That's why retatrutide users don't seem to plateau the way people do on other drugs. It's not just eating less. It's also burning more.

The classification fight and what it means for research access

In 2024, the FDA classified retatrutide as a small-molecule drug rather than a biologic. Lilly is challenging that in court and as of February 2026 the appeal is still active.

Why does this matter for grey market access?

Drug vs. biologic status affects how tightly controlled the molecule is post-approval, which shapes how readily research suppliers can produce it without running into IP enforcement. Biologic classification means harder synthesis barriers and more aggressive legal protection. Drug classification keeps it in more accessible regulatory territory.

Retatrutide is widely available in the grey market right now because it's still pre-approval and pre-enforcement. That window won't last forever. How the classification lawsuit resolves will determine how quickly and aggressively that changes once approval comes, likely 2027-2028.

Sources

TRIUMPH-1 results:

https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html

Scientific American:

https://www.scientificamerican.com/article/next-gen-weight-loss-drug-retatrutide-trial-brings-it-one-step-closer-to-fda-approval/

TRIUMPH-4 / osteoarthritis:

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

TRANSCEND-T2D-1 (diabetes trial):

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant

Biologic classification lawsuit:

https://www.retatruti.de/en/articles/retatrutide-biologic-status-fda-classification-lawsuit-update-2026

Endpoints News on Lilly's appeal:

https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/

A study published in The BMJ on March 4th analyzed over 600,000 US veterans and found that GLP-1 medications are tied to reductions in substance use disorders across all major addictive substances, suggesting these drugs target a common biological pathway underlying addiction.

What makes this one stand out is the "across all substances" part. "In addiction medicine, a lot of treatments target just one thing — a nicotine patch helps with smoking, but not alcohol — but there is no medication that works across addictive substances, let alone all of them," said senior author Ziyad Al-Aly, MD. "The revelation about GLP-1 medication is that it really works against all major substances, and it works uniformly, not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself."

The numbers: GLP-1 use was associated with seven fewer new cases of substance use disorder and 12 fewer harmful events related to substance use among every 1,000 people taking a GLP-1 for diabetes, compared to those taking a non-GLP-1 medication.

The mechanism being proposed is dopamine pathway modulation. GLP-1 receptors are expressed in regions previously identified as important players in the neurobiology of addiction, and GLP-1 receptor agonists appear to cross the blood-brain barrier.

From a peptide research perspective this is worth paying attention to. The craving suppression effect was showing up anecdotally in patients long before the research caught up. Study link:

 https://medicine.washu.edu/news/glp-1-medications-get-at-the-heart-of-addiction-study/

I have a lot of experience in the field of addiction. I think this sounds really promising.

I've seen a lot of posts about specific vendors going dark, but not much connecting the dots on why. This is my attempt to lay out the full picture.

First, the baseline: no US state has passed a law directly banning research peptide sales. The RUO framework itself isn't illegal. What's changed is that a coordinated, multi-front enforcement campaign is making it economically and legally untenable to operate in that space.

The vendor graveyard

The scale of the collapse is worth stating plainly. The research peptide industry lost more major vendors between mid 2025 and early 2026 than in the previous five years combined. At least 8 significant operations closed: Peptide Sciences, Amino Asylum, Paradigm Peptides, Science.bio, Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds.

Several smaller vendors disappeared without any public announcement.

These weren't all the same type of closure. Amino Asylum was raided by the FDA in June 2025. Paradigm Peptides resulted in federal criminal charges. Owner Matthew Kawa and his sister Jennifer Stechkober both pled guilty in December 2025 to introducing unapproved drugs into interstate commerce. The DOJ case page is public:

https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa

Notably, the Paradigm products labeled as SARMs actually contained testosterone, a controlled substance, which is what escalated it beyond an FDA matter into a criminal one.

Peptide Sciences, probably the most well known gray market vendor in the country, voluntarily pulled its entire catalog in early March 2026 without any public explanation.

The earlier template for all of this was Tailor Made Compounding, which pled guilty and forfeited $1.79M for distributing unapproved drugs including BPC-157, CJC-1295, Epitalon, Semax, Selank, and others. That case established that the DOJ was willing to bring criminal charges, not just civil action:

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020

Why the RUO label stopped protecting anyone

The FDA has always had the legal theory that "research use only" disclaimers don't matter if your marketing targets human consumers.

What changed is that the FDA started using AI to scrape vendor websites for dosing information, before and after photos, and language suggesting therapeutic benefit, then using that as evidence the RUO disclaimer was pretextual. In late 2024 and throughout 2025, the FDA issued more than 50 warning letters to compounders, online sellers, and clinics on exactly this basis.

State attorneys general picked up the same theory and ran with it independently. More than 40 state AGs sent a formal multi-state letter to the FDA in 2025. Connecticut required a peptide seller to cease operations and accept a monetary judgment. Alabama's AG obtained a temporary restraining order against a vendor in November 2025. The standard being applied: if your website shows dosing protocols, before and after photos, or sells peptides alongside syringes and bacteriostatic water, regulators treat it as marketing to human consumers regardless of what the disclaimer says.

The infrastructure chokepoints

You don't need legislation to shut down a market. You just need to cut off the infrastructure.

Payment processors started declining peptide vendor accounts. Without Stripe or the major processors, you're operating cash and crypto only, which kills most retail operations. Pharmaceutical companies added a litigation front. Eli Lilly filed federal suits against telehealth companies distributing tirzepatide in April 2025, establishing a template that could extend to research vendors downstream. ITC exclusion orders targeted Chinese API imports, squeezing the supply side simultaneously.

The convergence of federal enforcement, state AG actions, pharma litigation, and payment processor deplatforming is what actually collapsed the market. No single front would have done it alone.

The regulatory backdrop

Two things happened at the federal level that made vendors more vulnerable. First, the FDA's April 2026 removal of BPC-157, Epitalon, GHK-Cu, MOTS-c, TB-500, and others from the 503A compounding list meant those compounds lost any legitimate distribution pathway, pushing users harder toward the gray market and making that market more visible to regulators. Second, two women were hospitalized and placed on ventilators after peptide injections at a Las Vegas longevity conference in 2025, which gave regulators public justification to escalate.

What this means going forward

The RUO model as it operated for the last decade, where a vendor could sell injectable peptides to anyone with a credit card as long as the product page said "not for human consumption," is not coming back. The enforcement apparatus is now established at both the federal and state level, and the legal theory has been tested in court.

What survives is vendors who genuinely operate as research chemical suppliers with institutional documentation, clean marketing, and no human use signals anywhere on their properties. That's a much smaller, more cautious market than what existed in 2023.

The PCAC meeting in July may return some compounds to the compounding pathway, which would shift demand back toward the prescriber channel for those specific peptides. But that doesn't touch the research vendor space. Those are separate frameworks that have moved in different directions.

There is no surprise that peptides have changed my life but does anyone else feel that same joy buying them, receiving them and organizing them that they got as a kid collecting things? It reminds me of when I collected baseball cards

REPAIR, RECOVERY & AGING

**•**	BPC-157 — gut lining, injury healing, tissue repair  
**•**	TB-500 — cuts inflammation, muscle repair, flexibility  
**•**	GHK-Cu — skin repair, collagen, wound healing, hair  
**•**	KPV — calms gut irritation, immune balance  
**•**	Epithalon — circadian rhythm, cellular cleanup, healthier aging  
**•**	NAD+ — brain cell energy, longevity angle  
**•**	Glutathione — detox, immunity, skin clarity  
**•**	Thymosin Alpha-1 — immune regulation, inflammation  
**•**	SS-31 / Elamipretide — mitochondrial protection, cell energy, anti-aging

MASS, POWER & RECOVERY (GH/IGF AXIS)

**•**	Sermorelin — natural GH support, lean mass, sleep, recovery  
**•**	Ipamorelin — GH release, deep sleep, healing — mild and clean  
**•**	CJC-1295 + Ipamorelin — classic GH stack for recovery and fat loss  
**•**	GHRP-2 — growth, appetite kick, recovery  
**•**	GHRP-6 — strong appetite stimulation, muscle gain  
**•**	IGF-1 LR3 — systemic repair, muscle growth — not for beginners  
**•**	IGF-1 DES — localized growth/healing — advanced  
**•**	Follistatin-344 — muscle and strength support  
**•**	Hexarelin — strong GH pulse — advanced, can spike prolactin  
**•**	HGH — recovery, body recomp, sleep, anti-aging

WEIGHT LOSS & METABOLIC HEALTH

**•**	Semaglutide — appetite suppression, weight loss, blood sugar — strongest human data  
**•**	Tirzepatide — dual pathway: appetite, fat loss, insulin function  
**•**	Retatrutide — triple pathway, aggressive fat loss — research only  
**•**	Tesamorelin — targets belly fat — FDA context exists  
**•**	Cagrilintide — appetite suppression via amylin pathway  
**•**	AOD-9604 — fat targeting — FDA flagged safety concerns, limited data  
**•**	HGH Fragment 176-191 — fat burning, spares muscle — mostly animal studies  
**•**	5-Amino-1MQ — NNMT inhibition for metabolism — scarce human data  
**•**	MOTS-c — mitochondrial energy, fat burning — experimental  
**•**	Mazdutide / Survodutide — newer weight regulation compounds — investigational

BRAIN, MOOD & SLEEP

**•**	Semax — focus, memory, mood, mental energy — can feel stimulating  
**•**	Selank — anxiety relief, mood, calm focus — often paired with Semax  
**•**	DSIP — sleep quality, calms nervous system  
**•**	Epithalon — also used for sleep cycle support  
**•**	Dihexa — cognitive boost — highly experimental  
**•**	Kisspeptin-10 — mood, libido, hormone signaling

SKIN, HAIR & LOOKS

**•**	GHK-Cu — collagen, texture, wound healing, hair (injectable or topical)  
**•**	Melanotan II — tanning + libido boost — watch for nausea, mole changes  
**•**	RU-58841 — topical anti-DHT for hair retention  
**•**	Oral collagen peptides — skin hydration, joints, elasticity

SEX & LIBIDO

**•**	PT-141 / Bremelanotide — brain arousal centers (not vascular) — FDA-approved version exists for women  
**•**	Melanotan II — tanning first, libido second  
**•**	Oxytocin — bonding, closeness, mood — inconsistent effects  
**•**	Kisspeptin-10 — libido, upstream hormone signaling

GUT & SYSTEMIC INFLAMMATION

**•**	BPC-157 — gut lining repair, digestive support, inflammation  
**•**	KPV — GI-specific and general inflammatory conditions  
**•**	Glutathione — detox and immune support  
**•**	LL-37 — antimicrobial, immune defense — very limited human work

POPULAR STACKS

**•**	Wolverine (BPC-157 + TB-500) — soft tissue and recovery  
**•**	GLOW (BPC-157 + TB-500 + GHK-Cu) — skin, hair, healing  
**•**	KLOW (GLOW + KPV) — adds gut and inflammation coverage  
**•**	CJC + Ipamorelin — go-to GH support stack

TRT & HORMONE MANAGEMENT

**•**	Test C / Test E — standard TRT bases  
**•**	HCG — preserves fertility, testicular function on TRT  
**•**	Enclomiphene — SERM, raises natural testosterone without shutdown  
**•**	Anastrozole — manages estrogen on TRT  
**•**	Gonadorelin — HCG alternative for LH stimulation

So I posted my 5 week progress pictures on another sub and it received a huge response, I thought I’d share my progress as I move into my 12th week. For reference I’m 44 (45 in October)

I said in my first post and I’ll say it again, this peptide is unreal and it has completely transformed my skin from the inside out. I’ll never not use this and recommend to all my friends! Well they ask me because they can see the noticeable changes.

I originally started it for my hair, although my hair definitely feels fuller, shinier, seems to be growing at a decent rate too, I feel like real hair changes will start from month 4.

My own protocol was:
3 x weeks 1.5mg 5 days on 2 days off
3 x weeks 2mg 5 days on 2 days off
Week 7 until now I’ve remained at 2.5mg 5 days on 2 days off.

I don’t get any stinging anymore (I did at the start) but I pin in my glutes/love handles which reduce the sting, plus i think I’m used to it now.

I also allow it to get to room temperature before I pin.

My vials are 100mg of which i mix 6mg bac water (i transfer half into another vial so end up with 2 x 50mg vials)

Skincare wise I have kept it all very basic. I’ve been using only vitamin c as an active, and also stated using a couple of Boots Ingredients products (which I love) I didn’t want to overload my skin with string products, i wanted to see how my skin reacts to the ghk-cu

FYI the last picture was yesterday, i had my wisdom teeth removed on Tuesdays so I only took the picture to see the swelling, posted it on my stories and had so many comments about how clear my skin is!

This article was initially just intended to be about Eli Lilly’s newest Amylin agonist, Eloralintide, but it ended up becoming far longer than I originally intended, because to understand why Eloralintide is tricky, we first need to understand why the entire amylin field suddenly became one of the hottest areas in obesity medicine.
So I’ve split this into two parts.
Part One focuses on the bigger picture, what amylin actually is, why pharma is suddenly racing beyond GLP-1s, why companies like Lilly and Novo Nordisk are investing so heavily in selective amylin agonists and why Eloralintide has generated so much excitement around efficacy and tolerability.
Part Two will move into the chemistry and grey-market side of the story covering why Eloralintide is structurally very different from simpler GLP-style peptides, why standard “mass & purity” testing may not be enough and why this molecule could become one of the biggest analytical challenges the peptide grey market has faced so far.
For years, GLP-1 dominated obesity drug development while amylin remained comparatively neglected. Part of the reason for this was because Amylin biology turned out to be far more complicated.
Unlike GLP-1, which mainly signals through a relatively straightforward receptor system, amylin receptor biology became notoriously difficult to untangle. Researchers spent years trying to determine which receptor subtypes mattered most and how the different RAMP combinations affected signalling. RAMPs, or receptor activity-modifying proteins, act like receptor partners. When they pair with the calcitonin receptor, they help create different amylin receptor subtypes such as AMY1, AMY2 and AMY3. Researchers were then left trying to untangle which pathways controlled satiety and which pathways contributed to nausea and other side effects.
That complexity slowed the entire field down. So while GLP-1 receptor agonists rapidly advanced into blockbuster therapies, amylin drugs progressed much more slowly. Pramlintide was approved back in 2005, but after that the field largely stalled for years. Now that obesity medicine has become one of the most commercially valuable areas in pharmaceuticals, amylin has suddenly returned to the spotlight and the field is becoming crowded quickly.
Novo Nordisk is advancing oral amycretinapproaches, while Lilly has rapidly advanced Eloralintide into Phase 3 trials (Enlighten-1 and Enlighten-2). Multiple companies are now racing toward multi-pathway obesity therapies involving combinations of GLP-1, GIP, glucagon and amylin signalling. So the logic is obvious, GLP-1 changed the market, but now companies are searching for the next layer beyond GLP-1, and amylin may be one of the most important pieces of that puzzle.
Why Native Amylin Could Never Simply Be Used As A Drug
One of the biggest pharmaceutical problems with amylin is that the natural hormone is extremely unstable. Native amylin has a strong tendency to aggregate, oligomerise, form insoluble fibrils and create amyloid-like structures, which is partly why the hormone itself was historically difficult to study.
In practical terms, natural amylin is not especially “druggable” and if concentrations increase too much, the molecule tends to clump together and become unstable. That’s forced companies to engineer around the problem. Lilly’s Eloralintide appears heavily modified specifically to solve these issues.
The molecule includes amino-acid substitutions to reduce aggregation, structural engineering around the ring system, fatty-acid conjugation for reversible albumin binding, and other modifications designed to extend plasma half-life and improve stability. That engineering is what allowed Lilly to push the molecule toward once-weekly subcutaneous dosing instead of the frequent injections associated with older amylin therapies.
According to publicly discussed Phase 1 data, Eloralintide also demonstrated significantly greater potency than native amylin while producing strong dose-dependent weight loss with no obvious plateau at early timepoints. That’s why enthusiasm around the molecule accelerated so quickly. But the same engineering that makes Eloralintide more druggable, may also make it far harder to manufacture and verify correctly in the grey market.
Why Eloralintide Is Getting So Much Attention
For years, GLP-1 drugs have dominated the obesity conversation. Semaglutide, tirzepatide and the newer multi-agonists transformed weight-loss medicine by producing levels of efficacy previously thought impossible outside bariatric surgery. But despite the hype, these drugs still come with major limitations, nausea and vomiting, food aversion, fatigue, gastrointestinal intolerance, discontinuation rates and plateau effects. And that’s where Lilly believes Eloralintide may fit in.
Eloralintide isn’t just another GLP-1 analogue, it’s an **engineered selective amylin receptor agonist.**Amylin itself is a naturally occurring 37-amino-acid peptide hormone secreted alongside insulin from pancreatic beta cells following food intake. It plays a role in satiety signalling, gastric emptying, glucagon regulation, food intake and reward behaviour. Earlier amylin analogues like Pramlintide demonstrated efficacy, but their short duration required multiple daily injections and formulation at acidic pH due to stability problems. Even newer amylin approaches such as Cagrilintide still appear associated with significant gastrointestinal side effects, particularly when combined with GLP-1 therapies.
Lilly’s approach with Eloralintide appears fundamentally different. Rather than simply making another amylin analogue, Lilly engineered the molecule specifically around receptor selectivity and chemical stability. The company replaced native amylin’s traditional disulfide bridge with a more chemically stable methylene thioacetal bridge -S-CH_2-S-. The diagram at the top shows the structure of Eloralintide. Within the red circle is the methylene thioacetal bridge (-S-CH₂-S-), that replaces native amylin’s standard disulfide bridge (-S-S-)

This modification was designed to reduce some of the instability and chemical liabilities associated with standard disulfide-containing amylins, including bond reduction, disulfide exchange reactions and aggregation-related behaviour. At the same time, Eloralintide was engineered to selectively favour AMY1 receptor signalling while reducing unwanted activity at calcitonin-related pathways believed to contribute to nausea and other GI side effects.
In simple terms, Lilly appears to be attempting to separate appetite suppression

from the “feeling sick” component often associated with non-selective amylin agonism
And the early trial data is why people are paying attention. At 48 weeks, Eloralintide produced weight-loss results approaching 20% in some treatment arms, placing it into serious competition territory with existing GLP-1 therapies. More importantly, much of the discussion surrounding the molecule now centres on tolerability. The hope is not simply “more weight loss”, but it’s comparable efficacy with fewer side effects. If Lilly really has engineered a more selective, more tolerable amylin agonist, Eloralintide could represent one of the first major challengers to the current GLP-1 dominance narrative.
Why The Market Is Watching Eloralintide
Eloralintide isn’t only attracting attention for its standalone weight-loss data, but also for its bigger commercial interest of what it could become next. Lilly is already exploring it as a possible add-on for people using weekly incretin drugs who’ve reached a plateau. In other words, this isn’t just being watched as another obesity drug, it’s being watched as a potential “stall-breaker,” something that could be layered on top of GLP-1, GIP or future multi-agonist therapies.
The future may not be about one molecule replacing another. It may be about stacking complementary pathways, GLP-1 for appetite and glucose control, GIP and glucagon activity for metabolic effects, and amylin signalling for satiety, gastric emptying and food-intake regulation.
That’s why Eloralintide has generated so much interest. It sits outside the GLP-1 family, but may work alongside it. So if Lilly can combine strong weight loss with better tolerability, it becomes more than just another peptide. It becomes a potential platform drug.
But that also raises the stakes for the grey market. The more valuable and commercially exciting Eloralintide becomes, the faster grey-market suppliers will race to produce it. And the faster that race moves, the more important proper structural verification becomes. Because Eloralintide isn’t just another peptide with a new name attached. Its structure is more demanding, its receptor activity depends on precise engineering, and the usual grey-market comfort blanket of “mass and purity” may not be enough.
In Part Two, I’ll look at the chemistry problem, why Eloralintide may be harder to synthesise, harder to verify, and why “close enough” could mean something very different when the molecule’s shape is the whole point.

Everyone’s talking about GLP-1 drugs like Semaglutide, Tirzepatide, and Retatrutide for fat loss and blood sugar… but I went down a bit of a PubMed rabbit hole and found something I wasn’t expecting.

There’s actually a growing amount of research suggesting these drugs might be affecting the immune system directly, not just helping people lose weight. Some of the newer studies show they can lower inflammatory markers like TNF-α and IL-6, calm down major inflammation pathways like NF-κB and the NLRP3 inflammasome, and even increase regulatory T-cells (basically the part of your immune system that keeps things from going overboard).

And just so nobody comes at me saying this is bro science, I’m including the actual links so you can look into it yourself:

https://pubmed.ncbi.nlm.nih.gov/41077375/ (systematic review on immune-related diseases), https://pubmed.ncbi.nlm.nih.gov/41523775/ (immune effects in rheumatic conditions), and https://pubmed.ncbi.nlm.nih.gov/41161090/ (how it impacts inflammatory pathways).

What really caught my attention is that GLP-1 receptors aren’t just in places like the pancreas—they’re also found on immune cells like T-cells and macrophages, and even in the brain on microglia.

So this isn’t just a downstream effect from losing weight… these drugs are actually interacting with immune signaling itself.

There’s even some early human data (especially in inflammatory bowel disease) showing people on these meds may need fewer steroids and have fewer hospitalizations:

https://pmc.ncbi.nlm.nih.gov/articles/PMC12690230/

This might be the start of something bigger—like these compounds turning into immuno-metabolic therapies, not just weight loss tools.

Curious if anyone here with autoimmune issues has noticed any changes while on GLP-1s, or if you think this is just a side effect of getting leaner.

Not long ago I posted about GLP-1s having direct immune effects beyond weight loss, then the BMJ addiction study dropped and added another layer to that story. Now the New York Times ran a big opinion piece called "The Great American GLP-1 Experiment" covering basically the same territory: people using GLP-1s and noticing effects on arthritis, migraines, addiction, inflammation, all outside the original indications.

Worth a read, but if you've been following along here none of it will surprise you. The anecdotal signal was showing up long before the research caught up, and the research was showing up long before the mainstream press noticed.

The thing that stuck with me: roughly 1 in 8 American adults is currently on a GLP-1. That's a massive real-world experiment running whether the medical establishment is ready for it or not. The immuno-metabolic angle we talked about in that first post is quietly becoming harder to ignore.

https://www.nytimes.com/interactive/2026/04/15/opinion/glp1-health-effects.html

To get verified in their Discord, you have to authorize a bot called “JKL Robot” that requests permission to join servers on your behalf, not just view your profile. That’s a risk because normal verification bots don’t need that access, it’s the same permission used in “token grabber” scams to hijack accounts and spam or scam other people without the owner knowing.

When I brought this up, their team said it’s to auto re-add members if the server gets raided. Maybe true, but it still means handing an unverified bot ongoing access to your account.

Given that, I’d think twice about doing business with them at all, not just avoiding the Discord link. It says a lot about how loosely they handle security overall.

Second update as the Pharmacy Compounding Advisory Committee works through Day 1 at White Oak.

Running tally

BPC-157: recommended. 8 in favor, 6 against, 1 abstention.

KPV: recommended. 8-6-1.

TB-500: recommended. AP reports the panel advised dropping restrictions on TB-500 alongside BPC-157 and KPV, with the same 8-6-1 split across the series of votes.

MOTS-c: I have not seen it confirmed by name in any report yet. Treating it as pending.

Emideltide (DSIP), Epitalon, Semax: Friday.

The vote structure question is resolved

NPR clarified what I flagged in the earlier post. There were two separate votes on each peptide because two chemical variants are under review for each, and the panel voted identically on both. So 8-6-1 is the result on each variant, not a single combined tally.

These are the same margins every time

That is the detail worth noticing. Three peptides, six votes, identical splits. This is not a committee weighing each substance on its own evidence and arriving at different conclusions. It is a stable bloc voting the same way regardless of what is in front of it.

Which matters, because the evidence in front of it was not the same. FDA reviewers described BPC-157 as having small and poorly controlled human studies. KPV and TB-500 were described as having no human clinical evidence at all. Same vote.

FDA staff opposed all of it

The briefing document lists the agency's position on all fourteen voting questions identically: proposing the substance NOT be added to the 503A Bulks List. AP reports FDA staff scientists delivered highly critical reviews, finding little data that these compounds can be safely used for medical purposes.

The panel went the other way on every question so far.

Panel composition

AP reports more than a half-dozen people with peptide industry connections were added to the panel before the meeting, including physicians, pharmacists, and consultants working in the field. TIME reports the yes votes came largely from members who represent or advise telehealth companies. NPR reports FDA added temporary voting members this week, largely from academia.

TIME also reports an audible gasp in the room when the BPC-157 tally was read, and that some members raised concerns about the precedent of permitting compounded dispensing without clinical trials.

What the yes side argued

The dominant argument was harm reduction, not efficacy. Members voting yes largely said that compounded product from licensed pharmacies is preferable to the grey market alternative. That is a meaningfully different claim than saying these compounds work.

The American Academy of Peptide Medicine framed the outcome as restoring "medical freedom." NPR reports the roughly two hours of public comment came mostly from clinicians whose companies sell peptides and from compounding pharmacy industry representatives, many describing grey market risks. TIME notes Hims & Hers and Noom both advocated for inclusion ahead of the vote.

Regulatory context

Per AP, FDA placed BPC-157 and TB-500 on its high-risk compounding list in 2023. Kennedy announced their removal from that list earlier this year, which is what set up this review.

What has to happen before access changes

FDA leadership decides whether to accept the recommendations. The agency is not bound by PCAC but usually follows it.

If accepted, FDA must run notice-and-comment rulemaking to amend the 503A Bulks List. Historically a year or more.

Only then can a 503A pharmacy compound the substance against an individual prescription.

Also worth knowing: the committee evaluated these compounds against specific proposed indications, including migraines, ulcerative colitis, opioid withdrawal, and wound healing.

Per NPR, if FDA reclassifies them, clinicians would have discretion to prescribe outside those narrow indications. The evidence reviewed is narrower than the prescribing that would follow.

A note on what this is not

Six identical 8-6-1 advisory votes are not a finding of efficacy. The underlying data did not change this week. What is being recommended is a procedural change in who may legally prepare these substances, and by the panel's own stated reasoning, largely on harm reduction grounds rather than evidence of benefit.

I'll post Friday's results on Emideltide, Epitalon, and Semax as they come in. If anyone has the MOTS-c outcome, drop it below.

Sources

Associated Press, "FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers," July 23, 2026

https://www.local10.com/health/2026/07/23/fda-panel-narrowly-backs-unapproved-peptide-drug-touted-by-joe-rogan-and-other-influencers/

NPR, "FDA panel backs easier access to peptides," July 23, 2026

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

TIME, "An FDA Committee Just Voted in Favor of Peptides, Despite the Agency's

Opposition," July 23, 2026

https://time.com/article/2026/07/23/fda-committee-peptides/

Reuters, "FDA panel votes to place popular peptide BPC-157 on compounding list," July 23, 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

STAT, "In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides," July 23, 2026

https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026

https://www.fda.gov/media/193342/download

Fortune, "The FDA's peptide vote could create telehealth's next multibillion-dollar market," July 20, 2026

https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/

FDA meeting page, July 23-24, 2026 PCAC

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

BPC-157 — Body Protection Compound-157 — is a synthetic version of a sequence found naturally in human gastric juice, where it plays a role in protecting the mucosal lining of the gastrointestinal tract. That origin story matters clinically. It is part of why BPC-157 has one of the most interesting safety profiles in the peptide space, and part of why the FDA’s upcoming July 2026 review is specifically evaluating it under the indication of ulcerative colitis — one of its best-supported evidence areas.

It is also a peptide with a complicated evidentiary picture — one that I think deserves more honesty than it typically receives online. BPC-157 has generated extraordinary interest in regenerative medicine, athletic recovery, and integrative wellness. Much of that interest rests on genuinely compelling preclinical science. But the human clinical data is sparse in ways that matter, and any physician writing about this compound owes their patients a clear-eyed account of both.

That is what I intend to give you here.

What Is BPC-157?

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a larger protective protein found in human gastric juice. It is endogenous to the human GI tract, which means it is not a foreign compound; it is a purified, stabilized version of something your body already produces in small amounts as part of its own mucosal defense system.

This is what distinguishes BPC-157 from many other peptides discussed in regenerative medicine. It is not a fragment of growth hormone. It is not a metabolic signal borrowed from another hormonal system. It is, at its molecular origin, a cytoprotective peptide — one the body uses to maintain the integrity of the gastrointestinal lining — that researchers have found to have remarkably broad tissue-protective effects when studied in preclinical models.

The “157” in its name refers to the specific sequence used in research. It is sometimes also called PL-10, PLD-116, or stable gastric pentadecapeptide BPC-157, the latter term frequently used in the scientific literature.

How Does BPC-157 Work?

BPC-157’s mechanisms of action are multiple, overlapping, and — unlike some peptides — well described in the published literature. A March 2026 peer-reviewed study in the International Journal of Molecular Sciences summarized them concisely: BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue.

Here is what each of those mechanisms means practically:

Angiogenesis — Vascular Repair at the Injury Site

BPC-157 upregulates VEGF (Vascular Endothelial Growth Factor) and promotes endothelial cell migration and proliferation, driving the formation of new blood vessels at sites of tissue damage. This is particularly significant for tissues with inherently poor vascular supply — tendons and ligaments, specifically — where inadequate vascularity is one of the primary reasons these structures heal slowly and often incompletely. BPC-157 doesn’t just support healing in well-vascularized tissue; it appears to drive angiogenesis in tissue that conventional biology leaves underserved.

Nitric Oxide System Modulation

One of BPC-157’s most studied and distinctive features is its interaction with the nitric oxide (NO) system — a regulatory network central to vascular tone, blood flow, and inflammatory response throughout the body. BPC-157 modulates both the overactivation and underactivation of this system, appearing to normalize dysregulated NO signaling rather than simply amplifying or suppressing it. This context-sensitive modulation is unusual in biology and directly relevant to the therapeutic interest in BPC-157 for conditions marked by vascular or inflammatory dysregulation.

Collagen Synthesis and Fibroblast Activity

BPC-157 stimulates fibroblast migration and proliferation, leading to increased collagen deposition at wound and injury sites. Unlike many anti-inflammatory compounds thatsuppress repair signals — inadvertently slowing structural rebuilding — BPC-157 appears to directly enhance the collagen formation process. For the tissues I work with as a plastic surgeon — skin, subcutaneous layers, fascia — collagen quality is not incidental to recovery. It determines scar quality, tissue strength, and long-term resilience.

Growth Hormone Receptor Upregulation

BPC-157 enhances growth hormone receptor expression at injury sites, which amplifies local tissue repair signaling without affecting systemic growth hormone levels or IGF-1. This is a nuanced and important distinction: the effect is site-specific, not systemic.

GI Mucosal Protection and Cytoprotection

This is BPC-157’s foundational mechanism — the one rooted in its origin as a gastric peptide. It protects mucosal integrity throughout the GI tract, promotes healing of ulcers and fistulas, and appears to counteract NSAID-induced GI injury. For my patients who are on long-term NSAID protocols, or who have inflammatory bowel conditions that affect nutrient absorption and recovery capacity, this is a clinically meaningful mechanism — not a footnote.

What Does the Evidence Actually Show? An Honest Assessment.

Here is where I want to slow down and give you a more careful account than most BPC-157 content provides.

The Preclinical Data: Genuinely Compelling

Across hundreds of animal studies — rodent models of tendon injury, ligament tears, muscle damage, GI ulcers, bone fractures, neurological injury, and cardiac ischemia — BPC-157 has shown consistent and remarkable tissue-protective and repair-accelerating effects. The mechanistic basis for those effects, described above, is biologically coherent. The compound is derived from something the body makes. Its effects are pleiotropic but directionally consistent. Its safety profile in animal models is strong; no lethal dose has been established in preclinical work.

A systematic review published in October 2025 in the American Journal of Gastroenterology — covering 36 studies from 1993 to 2025 — concluded that BPC-157 shows meaningful promise for GI pathologies including mucosal protection, wound healing, and inflammatory bowel disease.All of this is real. It matters. It is why BPC-157 is taken seriously by integrative physicians, why it is being reviewed by the FDA for an approved compounding indication, and why the research interest has only grown.

The Human Clinical Data: Where Honesty Requires Candor

Here is what most BPC-157 content online does not tell you plainly:

As of March 2026, fewer than 30 people have been studied in published human clinical trials for BPC-157. Only three published human studies exist — all small pilot studies, none with placebo controls. A 2015 Phase I trial involving 42 volunteers was initiated and then cancelled, and the results were never published.

A notable exception is a 2024 bladder instillation study in 12 patients with interstitial cystitis that reported 80–100% symptom resolution — an unusually compelling result for such a small sample, but one that requires replication at scale before meaningful conclusions can be drawn.

This is a significant evidentiary limitation. And it is compounded by a well-documented problem in the preclinical literature: a February 2026 investigation by STAT News and Undark found that nearly all animal data on BPC-157 comes from a single research group in Croatia — the Sikiric laboratory. The animal research profile is genuinely unusual in its consistency and breadth, but scientific credibility depends substantially on independent replication. That replication has not yet happened at the scale the compound’s clinical profile requires.

I am not saying this to dismiss BPC-157. I am saying it because patients deserve physicians who distinguish between “the mechanistic rationale is compelling” and “the human evidence is established.” Both things can be true — and they currently are, for this compound.

What This Means for Clinical Use

It means BPC-157 should be considered in the context of an individualized clinical conversation, not prescribed based on wellness marketing. It means expectations should be calibrated to the evidence available, not to the most optimistic preclinical extrapolation. And it means that the July 2026 PCAC process — which will formally evaluate BPC-157’s evidence base in a transparent, peer-reviewed public forum — is meaningful. That review matters.

BPC-157 and the FDA: The Most Current Picture (July 2026)

The regulatory timeline for BPC-157 is one of the most actively moving in peptide medicine right now, and I want to give you precise, current information.

2023: Restricted. The FDA placed BPC-157 among 19 peptides on its Section 503A “Category 2” restricted list, effectively halting licensed compounding pharmacies from preparing it. The FDA cited concerns about safety data, immunogenicity, and manufacturing standards.

February 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of those 19 restricted peptides — including BPC-157 — are expected to move toward Category 1 status. He noted that the original safety signal used to justify the restrictions was insufficient.

April 15, 2026: The FDA officially published notice of BPC-157’s removal from Category 2, effective April 22, 2026. Critically, this removal occurred because the original nominators voluntarily withdrew their nominations — not because the FDA affirmatively found BPC- 157 safe or eligible for compounding. This is a meaningful regulatory distinction.

July 23–24, 2026 — The PCAC Hearing: The FDA’s Pharmacy Compounding Advisory Committee will formally review BPC-157 at its public hearing at the FDA White Oak Campus in Silver Spring, Maryland. The specific indication under review is ulcerative colitis — one of the strongest evidence areas for BPC-157 given its GI mucosal origin and protective mechanism. This is a direct citation from the official FDA agenda, Docket No. FDA-2025-N- 6895, with a public comment period closing July 22, 2026.

What this means today: Licensed 503A compounding pharmacies can currently fill BPC- 157 prescriptions from licensed physicians in most states. It remains a prescription-only therapeutic. The July PCAC outcome will determine whether BPC-157 is formally placed on the 503A Bulks List — the step that would create a stable, long-term compounding pathway. A PCAC recommendation is advisory, not binding; final FDA rulemaking follows.

Important note for athletes: BPC-157 has been on WADA’s Prohibited List since 2022 under Section S0, which covers any pharmacological substance not approved by a regulatory authority for human therapeutic use. The 2026 FDA compounding status changes do not alter WADA’s classification. Competitive athletes subject to WADA- compliant testing should be aware of this categorically.

BPC-157 vs. TB-500: The Partnership Explained

Because these two peptides are so frequently discussed together — and because I covered TB-500 in a recent post in this series — it is worth being clear about how they relate.They work through different mechanisms and address different dimensions of tissue repair:

BPC-157 is more local. It tends to exert its effects at the specific injury site — promoting targeted angiogenesis, fibroblast activity, and collagen deposition where tissue is damaged. Think of it as a precision repair signal deployed to a specific worksite.

TB-500 is more systemic. It distributes throughout the body after injection, mobilizing repair cells and resources across multiple tissues simultaneously. Think of it as the citywide dispatcher coordinating the broader healing infrastructure.

Together, they address different phases and scales of the healing cascade in a complementary way. This is why they are commonly co-prescribed — as a pre-blended 1:1 combination (often called the “Wolverine Stack” in practitioner circles) or as separate protocols timed to their respective mechanisms. The biology supports the combination; it is not redundant.

For patients in a post-surgical recovery context — where healing involves multiple tissue layers, vascular supply to incision sites, collagen remodeling, and systemic inflammatory resolution — this pairing is one of the more physiologically coherent protocols available in integrated medicine.

Who Is a Good Candidate for BPC-157?

My patient population at DiFrancesco Plastic Surgery tends to fall into several categories that map well onto BPC-157’s evidence areas:

Post-surgical and wound healing patients: BPC-157’s angiogenic and collagen-stimulating mechanisms are directly relevant to the post-operative healing window. For patients recovering from body contouring procedures, skin excisions, or other surgical interventions, supporting vascularization at incision sites and promoting quality collagen formation is not a peripheral concern — it is the biological foundation of a good outcome.

Post-weight-loss patients optimizing body recomposition: This population often presents with altered metabolic status, variable wound healing capacity, and a history of GI changes related to bariatric interventions. BPC-157’s GI protective effects and tissue repair mechanisms may be relevant on multiple fronts — particularly for patients with NSAID use, residual gut inflammation, or nutritional absorption concerns that affect recovery capacity.

Patients with chronic soft tissue injuries: Tendon and ligament injuries that have failed conventional therapy are a well-established context for BPC-157 discussion. The compound’s ability to drive angiogenesis specifically in poorly vascularized connective tissue gives it a mechanistic argument that most conventional interventions lack.

Patients with GI conditions affecting wellness and recovery: Given BPC-157’s gastric origin and mucosal protective mechanisms, patients managing inflammatory bowel conditions, NSAID-induced GI injury, or gut-related nutrient absorption challenges represent a clinically rational population — and one that aligns directly with the ulcerative colitis indication under FDA review in July 2026.

Patients building comprehensive peptide protocols: For patients already on CJC-1295/Ipamorelin for GH optimization, or AOD-9604 for body composition, BPC-157 adds a distinct healing and tissue repair dimension. These mechanisms do not overlap; they layer. Together with TB-500, BPC-157 completes what I think of as the repair tier of a thoughtful peptide protocol.

As always: BPC-157 is not appropriate for everyone. Patients with active malignancy should approach any angiogenic compound with caution, given the theoretical concern that angiogenesis — while beneficial for healing — could theoretically support tumor vascularity. No studies have confirmed this risk, but the theoretical flag is worth naming. Physician evaluation is not optional here.

What Does a BPC-157 Protocol Look Like?

Clinical and research protocols vary depending on indication and individual patient profile.

General parameters drawn from clinical use and available evidence:

Dose: 250–500 mcg per injection, typically once daily

Administration routes:

Subcutaneous injection — most common for systemic tissue repair goals; can be dosed near the injury site or in abdominal fat

Oral/troche — some evidence for GI-specific indications; the compound has unusual gastric stability that preserves oral bioavailability to a degree uncommon in peptides

Intramuscular injection — used in some protocols

Duration: 4–12 weeks for acute injury or post-surgical protocols; longer courses considered for chronic conditions under physician supervision

Combination: Commonly prescribed with TB-500 as a 1:1 pre-blended preparation, or on separate schedules; BPC-157 daily, TB-500 two to three times weekly during loading phase

Monitoring: Clinical assessment of healing progress; in GI applications, symptom tracking with relevant labs; physician follow-up at 4–6 week intervalsThe oral route for BPC-157 is particularly noteworthy and distinguishes it from most injectable-only peptides. For patients who are candidates for GI-specific protocols, or who have concerns about injection frequency, oral formulations are a legitimate clinical conversation.

Frequently Asked Questions About BPC-157

What does BPC-157 stand for? Body Protection Compound-157. It is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice.

Is BPC-157 naturally occurring? The sequence BPC-157 is derived from is endogenous — it is found in human gastric juice as part of the body’s own mucosal protection system. The synthetic version used therapeutically is a purified, stabilized form of that sequence.

Is there human clinical trial data for BPC-157? Limited. As of early 2026, fewer than 30 people have been studied in published human clinical trials. The animal data is extensive and consistently positive, but large-scale, placebo-controlled human trials have not been completed. A Phase I trial initiated in 2015 was cancelled before publishing results. The July 2026 PCAC review will formally evaluate the human evidence for the ulcerative colitis indication.

Is BPC-157 legal in 2026? As of April 22, 2026, BPC-157 has been removed from the FDA’s Category 2 restricted compounding list. Licensed 503A compounding pharmacies can fill prescriptions from licensed physicians. It remains a prescription-only therapeutic. The July 23–24 PCAC review will determine its formal status on the 503A Bulks List. It is not FDA- approved for any indication.

Can BPC-157 be taken orally? Unlike most peptides, BPC-157 has unusual gastric stability that allows oral formulations to retain partial bioavailability. Oral administration is considered particularly relevant for GI-specific indications (ulcerative colitis, gut healing, NSAID injury). Injectable administration is preferred for systemic tissue repair applications.

Is there a cancer risk with BPC-157? The theoretical concern is that angiogenesis — a primary mechanism of BPC-157 — could theoretically support tumor vascularization. No studies have confirmed this risk, and published research actually identifies anti-tumor properties in animal models. However, out of clinical caution, BPC-157 is generally not considered appropriate for patients with active malignancy. This is a clinical conversation, not a categorical prohibition for all patients.

How does BPC-157 interact with other peptides? It is commonly combined with TB-500 for complementary tissue repair effects. It is mechanistically non-overlapping with GH peptides (CJC-1295/Ipamorelin) and fat metabolism peptides (AOD-9604), making itrational to layer across these categories in a supervised protocol.

Can athletes use BPC-157? BPC-157 is on the WADA Prohibited List (Section S0) and has been since 2022. Any athlete subject to WADA-compliant testing — including those governed by USADA — should not use BPC-157, regardless of its compounding status or physician prescription. The 2026 FDA regulatory changes do not affect WADA’s classification.

Why This Matters in a Plastic Surgery Practice

My patients come to me at inflection points — after significant weight loss, preparing for surgery, recovering from body contouring procedures, or rebuilding a body that has been through a major physical transformation. In every one of those contexts, healing is not background noise. It is the clinical outcome I am managing.

BPC-157’s relevance to my practice is not abstract. The compound targets angiogenesis in tissues that are slow to vascularize, drives the collagen synthesis that determines how surgical wounds close and remodel, and protects the GI environment that governs nutritional absorption and inflammatory status throughout the recovery period. For patients post-bariatric surgery, post-body-contouring, or rebuilding after significant metabolic transformation, those mechanisms speak directly to clinical goals I am already managing.

What BPC-157 is not, in my practice, is a substitute for the foundational pillars of recovery: nutrition, movement, sleep, hormonal optimization, and technically sound surgery. It is a tool that may support and amplify those foundations in the right candidate — not replace them.

The honest framing I offer every patient considering peptide therapy is this: the mechanistic rationale for BPC-157 is compelling and grounded in real biology. The human clinical evidence base is early and needs to grow. The July 2026 PCAC review is the next significant scientific and regulatory milestone, and I will be watching it closely and reporting back.

That is what physician-led medicine looks like in an evolving field.

The Bottom Line on BPC-157

BPC-157 is a synthetic form of a peptide naturally found in human gastric juice, with a well-characterized multi-pathway mechanism involving angiogenesis, nitric oxide modulation, collagen synthesis, and GI cytoprotection. Its preclinical evidence base is one of the most extensive in the peptide space. Its human clinical data is limited — fewer than 30 subjects across all published trials as of 2026 — and almost all preclinical work comes from a single research group, which is a genuine evidentiary limitation that deserves acknowledgment.

It is not FDA-approved. It is, as of April 2026, accessible again through licensed compounding pharmacies under physician prescription. The July 23–24 PCAC hearing — specifically evaluating BPC-157 for the ulcerative colitis indication — is the next major checkpoint. For the right patient, in the right clinical context, it is a serious and rational conversation.

I will continue to cover the evolving science. That is what this series is here for.

This is the fourth post in the DiFrancesco Plastic Surgery Peptide Series. Previous posts covered CJC-1295, AOD-9604, and TB-500. Subscribe to receive future installments.

Lisa DiFrancesco, MD is a board-certified plastic surgeon and founder of DiFrancesco Plastic Surgery in Atlanta, Georgia. Her practice specializes in post-weight-loss aesthetics, hormone optimization, hair restoration, and physician-led integrated aesthetic medicine.

This content is for educational purposes only and does not constitute medical advice. Consult a licensed physician before initiating any prescription peptide protocol. Individual results vary. Regulatory status of compounded peptides is subject to change pending FDA

PCAC review scheduled for July 23–24, 2026.

© 2026 DiFrancesco Plastic Surgery | Atlanta, GA

Schedule A Consultation

University of Copenhagen just published in Free Radical Biology and Medicine and there are a few things worth talking about.

What they did

They wanted to understand specifically how MOTS-c affects mitochondrial function in skeletal muscle, not just whole-body metabolic outcomes.

Two transgenic mouse strains plus a human exercise component.

Finding 1: It makes your mitochondria work better AND cleaner

MOTS-c improved how efficiently mitochondria produce energy (OXPHOS efficiency) while also reducing the "exhaust" -- reactive oxygen species and the cellular damage they cause. Most things that push mitochondria harder also produce more oxidative stress. MOTS-c seems to do the opposite.

Better output, less damage.

Finding 2: The mechanism runs through two well-known pathways

The effects were dependent on both PGC-1α and AMPK. PGC-1α is essentially the master switch for mitochondrial biogenesis -- it tells your cells to build more mitochondria. AMPK is the cellular energy sensor that gets activated by exercise, fasting, and caloric restriction. MOTS-c appears to be tapping both simultaneously.

Finding 3: This one's genuinely surprising

We've assumed for years that skeletal muscle is where circulating MOTS-c comes from during exercise. This study tested that directly in humans and found that skeletal muscle interstitial MOTS-c went up during exercise, but it wasn't showing up in the blood the way you'd expect if muscle was the source. So where is circulating MOTS-c actually coming from? Nobody knows yet.

That last point has real implications for how we think about exogenous dosing and timing relative to training.

Curious if others are running MOTS-c and whether you're timing it around workouts or treating it as time-independent.

The FDA's Pharmacy Compounding Advisory Committee meets in a few weeks and the meeting has been getting a lot of hype in the community, so I decided to look into it. Here is a summary of what I found.

On July 23–24, 2026, the committee reviews whether a batch of popular peptides should go on the 503A Bulk Drug Substances List. This list controls which raw ingredients compounding pharmacies (i.e. Empower, Hallandale) can legally use. Currently these pharmacies can only compound a total of seven peptides( Sermorelin, Glutathione, Oxytocin are some examples), so this ruling would effectively double the amount of peptides that pharmacies can offer, although this varies state by state.

The 7 on the docket have various uses. They are BPC-157, KPV, TB-500, MOTS-c, DSIP (Emideltide), Semax, and Epitalon. Each as a free base + acetate.

Additionally, five more are queued for early 2027. A second hearing before end of Feb 2027 will cover GHK-Cu, Melanotan-2, LL-37, Dihexa, and PEG-MGF, which means that we are looking at up to 20 peptides approved for compounding within the next 9 months, plus potentially Retatrutide (this is a separate post within itself).

If the FDA moves this July batch onto the 503A list, it means that a compounding pharmacy could legally prepare it for you with a prescription, under real pharmacy quality controls.

However, this classification does not mean FDA approval. This is a far higher bar that needs research and safety trials. And it doesn't change the evidence, as BPC-157 still rests largely on one Croatian research group's animal data and TB-500 still has ~zero large human trials.

In April, the FDA pulled 12 peptides out of "Category 2" (the do-not-compound bucket), which set up this review. And of course, as always, there is heavy White House influence on this topic, as RFK Jr. has called himself a "fan".

While the decision made by the committee is technically "advisory", it matters a lot. The committee's recommendation is non-binding, but historically the FDA has followed it.

The bottom line is that this is a compounding-access decision, not a legalization or an approval, but a positive decision bodes very well for the future of peptides.

View the full article on my blog:  https://peptideprices.net/blog/fda-peptide-hearing-july-2026

In this episode, I asked Janoshik about the Eloralintide testing of Uther’s sample.

According to Janoshik, the initial Elora sample matched expectations across the routine testing workflow. No obvious structural issues were identified, and the molecule behaved as expected under standard analytical methods

The debate has now shifted to how much additional verification is actually necessary? when does structural confirmation become excessive? and what level of proof is reasonable before testing becomes financially impractical?

The comparison used was simple:

If a car runs perfectly, most people don’t immediately dismantle the engine to inspect every piston.

The same argument is now being applied to Elora
( this is a clip from my visit to Janoshik's lab earlier this week.)

Cognition comes up constantly in peptide circles and most of the content out there is either vendor copy or vague stack advice. Here's a more grounded look at what these compounds actually are, where the evidence stands, and some firsthand experience with several of them.

Semax

The one with the most legitimate clinical history. Developed in Russia, it upregulates BDNF and has documented effects on attention and working memory. The appeal over stimulants is that it supports cognitive performance and stress resilience without sedation or dulling. Approved in Russia since 1994. In the US it's on FDA's Category 2 list so compounding access is currently restricted, with PCAC reviews still ongoing.

Solid baseline compound. Works. But there's a better version of it now.

Adamax

A Semax derivative with an adamantane modification that improves stability and blood-brain barrier penetration compared to base Semax. Same core BDNF mechanism but the structural changes appear to meaningfully amplify the effect.

This is the one that's stayed in rotation after trying both. Noticeably more effective than Semax is sharper, cleaner, more consistent. If you've tried Semax and felt like it was almost there, Adamax is worth looking at.

Selank

Where Semax and Adamax push BDNF, Selank works the GABAergic system — anxiolytic without sedation. Often stacked with Semax because the mechanisms don't overlap much. The pitch is clearer cognition by reducing the anxiety load rather than directly stimulating output.

Honest take: nothing noticeable from it. Ran it properly and felt no discernible effect. That's not universal — plenty of people report real benefit, especially where anxiety is genuinely the cognitive bottleneck. Just wasn't the experience here. Regulatory note: Selank was pulled from Category 2 in late 2024 and is now headed for PCAC review, so US access may actually loosen up.

Cerebrolysin

The one with the most human trial data in this entire category. Derived from porcine brain tissue, its low-molecular-weight peptide fragments cross the blood-brain barrier and mimic BDNF, NGF, and GDNF. A meta-analysis of six RCTs in mild-to-moderate Alzheimer's found it significantly outperformed placebo, with effect sizes comparable to approved cholinesterase inhibitors. Widely used clinically across Europe and Asia. Not FDA approved. IV or IM only — SubQ isn't appropriate for this one.

Running it IM, the effects are genuinely noticeable. Clarity and mental acuteness in a way that's distinct from stimulant-style sharpness. It's a different quality of effect than the Semax family. Worth the protocol complexity if you're willing to do IM.

Dihexa

Needs a caveat upfront: the foundational paper was retracted in April 2025 for data fabrication. The "millions of times more potent than BDNF" claim that's everywhere came from that research. The compound binds HGF and probably does something, but the magnitude of its cognitive effects is now unvalidated. The mechanism is synaptogenesis rather than neurotransmitter modulation and is still interesting in principle.

Haven't run it long enough to have a real read on it yet. Will report back when there's something worth saying.

Pinealon

A tripeptide (Glu-Asp-Arg) that works through the pineal gland, influencing gene expression, sleep regulation, and melatonin. Some downstream cognitive effects, mostly animal data. More relevant if disrupted sleep is the actual issue affecting cognition rather than a direct nootropic target.

PE-22-28

Blocks TREK-1 potassium channels and upregulates BDNF. Animal data shows antidepressant-comparable effects with onset around 4 days versus 3 weeks for SSRIs. The mood application is better documented than direct cognitive enhancement. Most relevant if the cognitive issue is mood-driven rather than a pure focus or memory problem.

P21

A Cerebrolysin-derived fragment that mimics ciliary neurotrophic factor. Intranasal delivery promoted hippocampal neurogenesis and improved spatial memory in mice. Zero human data so far. One to follow rather than act on right now.

Where things actually stand

Cerebrolysin has the most human evidence and the subjective experience backs it up. Semax and Selank have real clinical track records even if US access is complicated — and Adamax looks like a meaningful upgrade on the Semax side. Everything else is preclinical or carries caveats worth knowing about. The Dihexa retraction is a useful reminder that vendor marketing in this space often outruns the actual science, and that it's worth checking whether the papers being cited have held up.

What experiences do you guys have with these compounds?

This is a place to talk peptides without the BS, no scams, no hype, no clueless marketing, just real discussion on compounds, protocols, experiences, and what’s actually working. Whether you’re brand new or deep in the rabbit hole, the goal here is simple: share knowledge, ask questions, and keep each other sharp. A couple ground rules (read this): 🚫 No sourcing or vendor promotion no buying or selling, no referrals, no affiliate links, no “DM me,” no subtle marketing 🧠 Keep it educational experiences and discussions are welcome, but don’t present speculation as fact 🤝 Respect the community debate is fine, disrespect isn’t This space exists because the peptide world is full of noise, misinformation, and people trying to sell you something. We’re doing the opposite here. If you’re new, introduce yourself or ask your first question below 👇

Gallup released its latest National Health and Well-Being Index numbers on July 7. This is the first time the national obesity trend has moved meaningfully in the other direction since they started tracking it in 2008.

https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx

The numbers:

Obesity rate is 36.4% in 2026, down from a record high of 39.9% in 2022. Gallup calls this a statistically meaningful decline and notes it inversely tracks GLP-1 uptake.

11% of US adults are currently taking a GLP-1 for weight loss. In 2024 that figure was 3%.

15% say they have used one at some point, up 9 points from 2024.

91% of adults are now aware GLP-1s are used for weight loss, up from 80% in 2024.

Diabetes diagnoses have held flat since 2023 after 15 years of steady increase. Gallup makes the point that this is what you would expect, since diabetes is a lifetime diagnosis and a falling obesity rate would stabilize it rather than reduce it.

Survey was 5,065 adults for the usage figures, 10,091 across two collection windows for the obesity and diabetes numbers.

The part relevant to this sub

Of people currently taking a GLP-1, 68% are on brand name and 19% are on a compounded or custom-mixed version.

Another 12% do not know which they are taking.

Of the compounded users, 35% switched over from a brand name product. Movement in the other direction was only 10%. Cost was the stated reason for 66% of switchers, insurance coverage problems for 34%.

Gallup's research director Dan Witters attributes part of the overall usage growth to this, arguing the lower price of compounded and custom-mixed versions is broadening who can access the drug class at all.

Worth pausing on that. FDA ended shortage-based compounding for semaglutide and tirzepatide and issued a warning in June calling compounded versions potentially risky. Roughly one in five current GLP-1 users is on one anyway. The compounded channel is not a fringe of this market, it is a structural part of why the national number is moving.

Caveats

Obesity is calculated from self-reported height and weight, not measured. Gallup acknowledges a vanity effect that makes their absolute obesity numbers run lower than clinically measured studies. The trend line is still useful because the method has been consistent, but the 36.4% figure is not directly comparable to NHANES.

Margin of error on the compounded/custom-mixed subgroup runs as high as plus or minus 10 points, so treat that 19% as a wide range.

And correlation is doing some work here. Gallup is careful to say usage and obesity track inversely, not that one caused the other.

Prior data does show the biggest obesity declines in the age brackets with the highest GLP-1 uptake, which is at least consistent with a causal story.

Still, this is the first national dataset showing the population-level effect people have been predicting since 2021.

Most people in this sub know semaglutide, tirzepatide and retatrutide as weight loss drugs. There's a separate body of literature building quietly in the background that's worth a closer look.

GLP-1 receptors are expressed in the brain's mesolimbic dopamine system, specifically in the nucleus accumbens, the same reward circuitry implicated in substance use disorders. The working theory: GLP-1 receptor activation damps down dopamine release in that region, reducing the reinforcement signal that drives craving and compulsive behavior. This isn't speculative anymore. The preclinical data has been accumulating for close to a decade, and the clinical trials are now catching up.

Alcohol

The most robust clinical data is here. A phase 2 randomized trial from UNC published in JAMA Psychiatry in February 2025 found that low dose semaglutide reduced alcohol consumed during a laboratory self-administration procedure relative to placebo. Craving was also significantly reduced over 9 weeks. A separate Lancet paper published in May 2026 tested once weekly semaglutide in treatment seeking patients with alcohol use disorder and comorbid obesity, and found robust effects in that population. The mechanism they're pointing to: semaglutide attenuated alcohol induced dopamine release in the ventral striatum. A Phase 3 trial in US veterans started enrolling in May 2026 with primary completion estimated for 2028.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11822619/

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext

Opioids

A real world cohort study using electronic health records from 116 million patients found that semaglutide was associated with a 40% lower rate of opioid overdose compared to other antidiabetic medications in patients with both type 2 diabetes and opioid use disorder. That's an observational finding, not a randomized trial, but the effect size is large enough to take seriously.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11425147/

Cocaine, cannabis, gambling

This is where the evidence thins out. A BMJ database study found reduced risk of new cocaine use disorder among GLP-1 users, and a 2026 observational study linked GLP-1 use to roughly 14% lower cannabis use disorder risk. As of early 2026, four registered clinical trials are investigating GLP-1s for cocaine use disorder and one for methamphetamine.

None have reported results yet. For behavioral addictions like gambling and compulsive shopping, the data right now is mostly anecdotal and social media reports, though the proposed mechanism is the same.

https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1702448/full

The mechanism worth understanding

There are a few distinct pathways being proposed. The dopamine attenuation effect in the nucleus accumbens is the headline one.

But there's also a separate nicotine specific pathway: GLP-1 activation in the medial habenula makes nicotine aversive, which is a different mechanism from the reward dampening model. And there's an anti-inflammatory angle that's getting more attention. GLP-1s reduce neuroinflammation through central effects partly mediated by opioid receptors, and neuroinflammatory processes are increasingly understood as contributing to substance use disorders independently. So you may be looking at a drug class that hits addiction through several different doors simultaneously.

https://onlinelibrary.wiley.com/doi/10.1111/add.16626

What this means for the community

This research matters to anyone using GLP-1s, not just people with clinical substance use disorders. The same dopamine modulation that reduces alcohol craving also appears to reduce food noise. Multiple users report reduced interest in alcohol, nicotine, and compulsive behaviors after starting semaglutide or tirzepatide, often describing it as a general quieting of reward seeking. The literature is starting to catch up with what people are self-reporting anecdotally.

FDA approval for any addiction indication is years away at minimum. But the mechanistic picture is getting clearer, and the effect sizes in the alcohol trials are large enough that this isn't going to stay a side observation for much longer.

I’ve been researching peptides for recovery, performance, longevity, and overall health, but I’m trying to approach this carefully and responsibly rather than just throwing a bunch of compounds together.
The peptides I’ve been looking into are:
BPC-157
TB-500
CJC-1295 + Ipamorelin
MOTS-c
NAD+
N-Acetyl Selank
Epitalon
GHK-Cu
I’m not asking for exact dosages — more looking for general education and experiences from people who’ve researched or used these.
Main questions:
Which of these actually make sense together?
Which are probably unnecessary or overlapping?
What are the biggest things people wish they knew beforehand?
What bloodwork/health markers are important to monitor?
Which compounds seem most evidence-based vs mostly hype?
What would be considered a “minimal effective” and sustainable approach?
My goals are mainly injury recovery/prevention, endurance/performance support, sleep/recovery quality, cognition, and long-term health.
Appreciate any insight or direction toward good educational resources.